Acurx Pharmaceuticals Secures New Patent in Australia for Groundbreaking Antibiotic Technology

Acurx Pharmaceuticals, Inc., a prominent player in the biopharmaceutical sector listed on NASDAQ as ACXP, has recently been granted a significant academic milestone by the Australian Patent Office. This patent, awarded on October 9, 2025, is focused on DNA Polymerase IIIC inhibitors—part of the company's innovative approach to combat difficult-to-treat bacterial infections through a new line of small-molecule antibiotics.

The granting of this new patent is pivotal for Acurx as it complements the company’s existing portfolio, which already includes several granted patents across various countries, including the U.S., Israel, Japan, and India. Specifically, the patent covers compositions-of-matter relevant to the ACX-375C program, aligning with Acurx's strategic aim to protect their developments in the antimicrobial arena. Presently, Acurx is working on advancing its FDA-approved antibiotic candidates while also engaging in ongoing patent applications across additional territories, thus reinforcing their global intellectual property footprint.

Robert J. DeLuccia, the Executive Chairman of Acurx, stated, “Achieving this patent in Australia adds to our growing number of countries where we are patent protected for a long period as we further develop our innovative, AI-supported drug discovery platform of second-generation DNA pol IIIC inhibitors.” He emphasized that the new compounds represent a potential shift in antibiotic treatment strategies aimed at multidrug-resistant Gram-positive pathogens such as Staphylococcus aureus, inclusive of strains that are notoriously difficult to treat, like MRSA and VRE.

Furthermore, these new compounds are believed to exhibit activity against B. anthracis, the bacterium responsible for anthrax, which is categorized as a Bioterrorism Category A threat-level pathogen. This highlights Acurx’s commitment not only to the development of cutting-edge medical technologies but also to addressing critical public health issues through innovative scientific advancements.

In terms of product development, Acurx's lead DNA Polymerase IIIC inhibitor is anticipated to be Phase 3-ready for oral treatment of C. difficile infections, and has successfully validated the bacterial target for its DNA Polymerase inhibitors. Moreover, the company is venturing into the preclinical phase with promising compounds that are set to be absorbed systemically, providing potential for both oral and parenteral use in clinical scenarios that include, but are not limited to, acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and various other serious bacterial infections.

Acurx Pharmaceuticals aims to take full advantage of its technological advancements as it plans to initiate international clinical trials for its lead product candidate, ibezapolstat, at the earliest opportunity. The company’s product pipeline underscores a robust focus on developing targeted antibiotic therapies specifically for infections linked to drug-resistant organisms, which pose a growing threat to global health systems.

In conclusion, the Australian patent is not just a formal acknowledgment of Acurx's innovative work; it signifies a leap forward in the company's journey toward becoming a pioneering force in antibiotic development. This achievement reinforces the necessity for advanced therapeutics in an era of rising antibiotic resistance and outlines a promising horizon both for patients and the healthcare industry at large.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. is dedicated to developing a revolutionary class of small molecule antibiotics specifically targeting challenging bacterial infections. The company employs a Gram-positive selective spectrum (GPSS®) approach, blocking enzymes critical for bacterial DNA replication, with a focus on Gram-positive bacteria that are often resistant to traditional treatment options. Learn more about Acurx's innovations by visiting www.acurxpharma.com.